Watson Confirms Favorable District Court Ruling in Androgel® 1% Antitrust Litigation

PARSIPPANY, N.J., Oct. 1, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that on September 28, 2012, the United States District Court for the Northern District

of Georgia granted summary judgment in favor of Watson, and all other defendants, on all remaining claims in the pending antitrust lawsuit related to settlements of patent litigation

concerning Androgel® 1% testosterone gel. 

The court found that the plaintiffs' claims were unsustainable because the underlying patent litigation was not objectively baseless and did not constitute sham litigation.  The court had

previously granted Watson's motion to dismiss all claims asserted by the Federal Trade Commission concerning the same settlement.  The United States Court of Appeals for the Eleventh Circuit

affirmed that dismissal.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic

pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. 

Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the world's established and growing

international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.   

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing

trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual

results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of

predicting the timing and outcome of the pending antitrust litigation, including appeals, and risks that an adverse outcome in such litigation could render Watson liable for substantial

damages; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of

predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the

Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and Watson's Annual Report on Form 10-K for the

year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

Sign up for free newsletters and get more CNBC delivered to your inbox

Get this delivered to your inbox, and more info about our products and services.

© 2025 CNBC LLC. All Rights Reserved. A Division of NBCUniversal